CagriSema vs Retatrutide
A side-by-side research comparison of CagriSema and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CagriSema | Retatrutide |
|---|---|---|
| Full name | CagriSema (Cagrilintide + Semaglutide) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | Combination product | 5,200 Da (approximate) |
| Half-life | 7 days (both components) | 6 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | Cagrilintide 2.4mg + Semaglutide 2.4mg | 1-2 mg → titrate up to 12 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.